Marshall Wace, LLP
- SEC CIK
- 0001318757
- Latest filing
- Aug 13, 2026
APLS holding history
Apellis Pharmaceuticals, Inc. in every 13F filed by Marshall Wace, LLP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
APLS overviewAll 13F holders of APLSFull Q2 2026 holdings
- Shares (Q2 2026)
- 0
- Sold out in Q2 2026
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 17
- Since Q2 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 0 | $0 | 0.0% | −929,019−100.0% | Sold out | Holders |
| Q1 2026 | 929,019 | $37.4M | <0.1% | −61,829−6.2% | Reduced | Holders |
| Q4 2025 | 990,848 | $24.9M | <0.1% | +594,113+149.8% | Added | Holders |
| Q3 2025 | 396,735 | $8.98M | <0.1% | −2,308,102−85.3% | Reduced | Holders |
| Q2 2025 | 2,704,837 | $46.8M | 0.1% | +2,681,263+11,373.8% | Added | Holders |
| Q1 2025 | 23,574 | $515.6K | <0.1% | −61,921−72.4% | Reduced | Holders |
| Q4 2024 | 85,495 | $2.73M | <0.1% | +63,705+292.4% | Added | Holders |
| Q3 2024 | 21,790 | $628.4K | <0.1% | +21,790 | New | Holders |
| Q2 2024 | 0 | $0 | 0.0% | −171,873−100.0% | Sold out | Holders |
| Q1 2024 | 171,873 | $10.1M | <0.1% | −59,003−25.6% | Reduced | Holders |
| Q4 2023 | 230,876 | $13.8M | <0.1% | +61,582+36.4% | Added | Holders |
| Q3 2023 | 169,294 | $6.44M | <0.1% | −173,058−50.5% | Reduced | Holders |
| Q2 2023 | 342,352 | $31.2M | 0.1% | +249,906+270.3% | Added | Holders |
| Q1 2023 | 92,446 | $6.10M | <0.1% | −343,977−78.8% | Reduced | Holders |
| Q4 2022 | 436,423 | $22.6M | 0.1% | +99,696+29.6% | Added | Holders |
| Q3 2022 | 336,727 | $23.0M | 0.1% | −1,031,680−75.4% | Reduced | Holders |
| Q2 2022 | 1,368,407 | $61.9M | 0.1% | +453,244+49.5% | Added | Holders |
| Q1 2022 | 915,163 | $46.5M | 0.1% | +915,163 | New | Holders |
| Q3 2021 | 0 | $0 | 0.0% | −10,375−100.0% | Sold out | Holders |
| Q2 2021 | 10,375 | $656.0K | <0.1% | +10,375 | New | Holders |